Monday, January 21, 2013

Shenzhen Neptunus Bioengineering submits first ever application for conducting Phase 2 trials in the US for Traditional Chinese Medicine ( Polydatin Injection) in the class of innovative drugs

Shenzhen Neptunus Bioengineering has submitted to the USFDA application for conducting Phase 2 clinical trials on its shock therapy ( Polydatin Injection )This is the first ever application for clinical trial research of Chinese medicine in the United States submitted a class of innovative medicines.
Polydatin is a Class I innovative traditional Chinese that aides microcirculation of the blood and is expected to be tested as a treatment for myocardial ischemia, cerebral ischemia, shock and other cardiovascular diseases

Enter your email address:


Delivered by FeedBurner